Concepedia

Elizabeth Ditty

ED

Statistics

Publications

6

Citations

144

H-Index

6

Active since

2020

Affiliations

Mersana Therapeutics (United States)(Current)

Elizabeth Ditty is an author at Mersana Therapeutics (United States) specializing in pharmacy, antibody-drug conjugates, and antibody-drug conjugate therapy.

ORCID

Publications per year

2020–2025

6

Publications

6

Discovery and Preclinical Characterization of XMT-1660, an Optimized B7-H4-Targeted Antibody–Drug Conjugate for the Treatment of Cancer

Dorin Toader, Shawn P. Fessler, Scott D. Collins et al. · Molecular Cancer Therapeutics · 2023 · 39 citations · Full text

, , +17

XMT-2056, a HER2-Directed STING Agonist Antibody–Drug Conjugate, Induces Innate Antitumor Immune Responses by Acting on Cancer Cells and Tumor-Resident Immune Cells

Raghida A. Bukhalid, Jeremy R. Duvall, Kelly L. Lancaster et al. · Clinical Cancer Research · 2025 · 36 citations · Full text

, , +17

Abstract 1738: XMT-2056, a well-tolerated, Immunosynthen-based STING-agonist antibody-drug conjugate which induces anti-tumor immune activity

Jeremy R. Duvall, Raghida A. Bukhalid, Naniye Mallı Cetinbas et al. · Cancer Research · 2021 · 24 citations

, , +17

Abstract 3503: XMT-2056, a HER2-targeted Immunosynthen STING-agonist antibody-drug conjugate, binds a novel epitope of HER2 and shows increased anti-tumor activity in combination with trastuzumab and pertuzumab

Jeremy R. Duvall, Raghida A. Bukhalid, Naniye Mallı Cetinbas et al. · Cancer Research · 2022 · 24 citations

, , +17

Abstract 2894: XMT-1592, a site-specific Dolasynthen-based NaPi2b-targeted antibody-drug conjugate for the treatment of ovarian cancer and lung adenocarcinoma

Shawn P. Fessler, Anouk Dirksen, Scott D. Collins et al. · Cancer Research · 2020 · 11 citations

, , +16

1–5 of 6